Rikke E.
- Country
- Denmark
- Department
- Department of Oncology
Research Overview
- Evaluation of RO7276389 Monotherapy and Combination with Cobimetinib in BRAF-V600 Mutation-Positive Advanced Solid Tumors or Melanoma with CNS Metastases
- A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors
- Phase I/II Study of DF1001, Nivolumab, and Paclitaxel Albumin-Bound in Locally Advanced or Metastatic Solid Tumors
Data & Insights
Has run more than one trial at 18 of 66 partner sites.
Specializations
Advanced Oncology Research
The investigator specializes in treating advanced and metastatic solid tumors, with particular emphasis on developing innovative therapeutic approaches for patients with limited treatment options.
- Molecular-targeted therapies
- Immunotherapy combinations
- Biomarker-driven treatments
Specialized Cancer Focus
Demonstrates expertise in treating multiple cancer types including gynecological malignancies, gastrointestinal cancers, and genitourinary tumors. Notable work in BRAF-mutation positive cancers and tumors with specific genetic profiles.
- Endometrial and cervical cancers
- Biliary tract cancers
- Neuroendocrine tumors
Treatment Innovations
Actively involved in evaluating novel therapeutic agents including monoclonal antibodies and targeted anti-cancer drugs. Focuses on developing personalized treatment approaches based on genomic profiling.
- Novel drug combinations
- Precision medicine applications
- Immunotherapy optimization
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.